The human leukocyte antigen (HLA) typing for transplant market is witnessing significant growth globally, driven by increasing organ transplant procedures and advancements in transplantation techniques. HLA typing determines donor and recipient compatibility, reduces rejection risk, and improves transplant outcomes. The market is characterized by a growing demand for HLA typing in various applications, including solid organ transplantation, stem cell transplantation, and tissue compatibility testing. Technological advancements, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), have revolutionized HLA typing, offering higher resolution and accuracy. Moreover, the rising prevalence of chronic diseases leading to organ failure, coupled with the growing number of transplant procedures, is fueling market growth.
Global Human Leukocyte Antigen (HLA) Typing for Transplant Market was valued at USD 778.19 million in 2021 and is expected to reach USD 1,483.61 million by 2029, registering a CAGR of 8.4% during the forecast period of 2022-2029.
To know more, visit https://www.databridgemarketresearch.com/jp/reports/global-hla-typing-transplant-market
Below are the Top Five Human Leukocyte Antigen Typing for Transplant Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific Inc. is a leading company in the field of Human Leukocyte Antigen (HLA) Typing for the Transplant Market. The company offers a comprehensive range of products and services for HLA typing, catering to the needs of transplant centers, hospitals, and research institutions worldwide. Thermo Fisher's HLA typing solutions include molecular typing assays, sequencing instruments, software, and services that enable high-resolution HLA typing for improved transplant compatibility and patient outcomes. The company's innovative technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), provide accurate and reliable HLA typing results.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In January 2021, Thermo Fisher Scientific Inc. collaborated with Protein Metrics to provide advanced mass spectrometry data processing, and analysis capabilities to drive innovation across the full spectrum of biopharmaceutical and proteomics.
|
|
2.
|
Illumina, Inc.
|
Illumina, Inc. is a renowned leader in genomics and genetic analysis, making it a significant player in the Human Leukocyte Antigen (HLA) Typing for the Transplant Market. The company's innovative sequencing technologies, such as the NovaSeq and MiSeq systems, enable high-resolution HLA typing, which is critical for transplant compatibility assessment. Illumina's sequencing platforms offer exceptional accuracy, scalability, and cost-effectiveness, making them ideal for HLA typing in both research and clinical settings. In addition, Illumina provides a range of software solutions for data analysis and interpretation, enhancing the utility of its sequencing systems for HLA typing.
|
|
Americas, Middle East and Africa, Europe, Asia
|
In September 2019, Illumina, Inc. collaborated with the Broad Institute of MIT and Harvard for the development of secondary genomic software and algorithms. The company is investing in such innovation to deliver best–in–class open source software for common genomic testing methods. This initiative boosted the clinical adoption of sequencing methods by decreasing the overall cost and time of genome analysis.
|
|
3.
|
Bio-Rad Laboratories, Inc.
|
Bio-Rad Laboratories, Inc. is a prominent player in the Human Leukocyte Antigen (HLA) Typing for Transplant Market, offering a wide array of products and solutions for HLA typing and transplantation research. The company's product portfolio includes HLA typing kits, PCR instrumentation, and software for data analysis, providing comprehensive solutions for HLA genotyping and compatibility testing. Bio-Rad's HLA typing products are known for their accuracy, reliability, and ease of use, making them popular among transplant centers and research laboratories worldwide. In addition, Bio-Rad offers a range of services, including technical support and training, to ensure the successful implementation of its HLA typing solutions.
|
|
North America, Europe, Latin America, Asia
|
In August 2021, Bio-Rad Laboratories, Inc. participated in a Fireside Chat at the 2021 Virtual Wells Fargo Healthcare Conference. This conference helped the company to furnish correct knowledge about their products in the market.
|
|
4.
|
QIAGEN
|
QIAGEN is a global leader in sample preparation technologies for HLA typing and transplant diagnostics. The company offers a comprehensive range of products and services for HLA typing, including PCR-based assays, sequencing instruments, and software solutions. QIAGEN's HLA typing products are known for their accuracy, reliability, and ease of use, making them ideal for transplant compatibility testing. The company also provides a range of services, including technical support and training, to ensure the successful implementation of its HLA typing solutions.
|
|
North America, Middle East and Africa, Europe, Asia- Pacific
|
In September 2020, QIAGEN announced the acquisition of NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems. This acquisition helped in the growth of the company and in revenue generation due to the increased demand of PCR products in the market.
|
Conclusion
The human leukocyte antigen (HLA) typing for transplant market is experiencing significant growth, driven by increasing demand for transplant procedures and advancements in HLA typing technologies. Companies like Thermo Fisher Scientific, Illumina, Bio-Rad Laboratories, and QIAGEN are key players in this market, offering a wide range of products and services for HLA typing. These companies provide innovative solutions that ensure accurate and reliable HLA typing, leading to improved transplant outcomes. Despite challenges such as high costs and organ donor shortages, the market is expected to continue growing as the focus on personalized medicine and innovative HLA typing techniques increases. Overall, the market for HLA typing in transplantation is poised for continued expansion and development.
